Table 1.

Patient characteristics of transplanted AML cases.

Case	Tissue	Age	Gender	WBC count	FAB type	ELN 2017 risk	Recurrent mutations	Karyotype
AML-4	BM	39	Female	3,4	M4	Adverse	FLT3-ITD	NK
AML-7	BM	60	Female	8,2	M4	Favorable	FLT3-TKD, IDH2, NPM1, WT1	NK
AML-9	PB	48	Female	25,3	M5	Favorable	DNMT3A, TET2, NPM1	NK
AML-10	PB	72	Male	21,1	M4	Adverse	ASXL1, IDH2, JAK2, RUNX1	inv(9)(p11q12)
AML-11d	PB	64	Female	58,0	M5	Favorable	CDKN2A, DNMT3A, KRAS, NPM1, TET2, U2AF	+8
AML-11r	BM	66	Female	15,6	M2	Intermediate	DNMT3A, RUNX1, TET2, U2AF	+8
AML-16	BM	64	Male	24,9	M1	Favorable	FLT3-TKD, NPM1, STAG2, TET2	NK
AML-17	PB	73	Male	12,1	M5	Intermediate	DNMT3A, GATA2, NPM1, NRAS	NK
AML-20	PB	41	Male	39,1	M4	Favorable	CBFB/MYH11, NRAS	inv(16)(p13q22)
AML-21	BM	70	Male	76,0	M2	Intermediate	BCOR, IDH2, NRAS, STAG2	NK
AML-24	BM	72	Male	5,5	M2	Favorable	IDH2, NPM1	NK
AML-25	BM	86	Male	2,2	M2	Favorable	NPM1, TET2	−Y
AML-26	PB	59	Female	91,9	M4	Favorable	DNMT3A, IDH2, NPM1	NA
AML-27	PB	59	Male	47,0	M1	Intermediate	IDH1, NPM1	NK
AML-28	BM	67	Male	37,5	M2	Intermediate	FLT3-ITD, NPM1, TET2	NK
AML-33r	PB	43	Female	83,3	M4	Intermediate	FLT3-ITD, IDH1, NPM1	NK
AML-34	BM	50	Female	35,0	M5	Intermediate	CEBPA, DNMT3A, IDH1, NRAS	NK
AML-37	BM	73	Male	19,0	M5	Adverse	CDKN2A, FLT3-TKD, TP53	Complex
AML-47r	BM	35	Male	24,0	M1	Adverse	BCOR, FLT3-TKD, PTPN11, RUNX1	NK
AML-48	PB	82	Female	58	M2	Adverse	TP53	Complex
AML-54	BM	58	Male	2,2	M2	Adverse	RUNX1, EZH2, BCOR, ETV6, CEBPA	−7, +8
AML-67	PB	63	Female	15,1	M4	Favorable	DNMT3A, NPM1, RUNX1T1, TET2	NK
AML-74	PB	47	Male	4,9	M2	Intermediate	IDH1	del(12)(p11p13)
AML-79	PB	58	Male	73,0	M4	Intermediate	FLT3-ITD, IDH2, NPM1	NK
AML-83	BM	72	Male	25,9	M2	Adverse	NF1, TET2, TP53	Complex
AML-107r	BM	42	Female	2,5	M2	Adverse	TP53, CBL	Complex